Lecap Asset Management Ltd. Purchases Shares of 689 Eli Lilly and Company (NYSE:LLY)

Lecap Asset Management Ltd. bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 689 shares of the company’s stock, valued at approximately $402,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Thompson Investment Management Inc. purchased a new stake in Eli Lilly and Company in the 3rd quarter worth $27,000. Retirement Group LLC raised its holdings in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $33,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at approximately $35,000. Finally, Optiver Holding B.V. purchased a new stake in Eli Lilly and Company during the third quarter valued at $36,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Finally, Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 133,785 shares of company stock worth $86,537,034. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $751.64 on Monday. The firm has a market capitalization of $714.18 billion, a PE ratio of 129.59, a PEG ratio of 1.65 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a twelve month low of $367.35 and a twelve month high of $800.78. The firm’s 50-day moving average price is $761.77 and its 200 day moving average price is $654.08.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business earned $2.09 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and Company will post 12.46 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.